INTRODUCTION
============

A significant number of mesenchymal stem cells (MSCs) are needed for clinical applications which require extensive MSC expansion in culture. However, differentiation potential of bone marrow (BM) and adipose-derived MSCs at later passage is often low. In addition, there are several negative reports on MSC senescence ([@b3-ajas-26-4-588-19]; [@b11-ajas-26-4-588-19]; Gruber et al., 2011) or tumor transformation ([@b18-ajas-26-4-588-19]; [@b17-ajas-26-4-588-19].

Canine derived multipotent MSCs have been established from umbilical cord ([@b16-ajas-26-4-588-19]; [@b21-ajas-26-4-588-19]; [@b20-ajas-26-4-588-19]), umbilical cord vein ([@b32-ajas-26-4-588-19]), and umbilical cord blood ([@b22-ajas-26-4-588-19]). Interestingly, recent research has demonstrated that adipose derived stem cells are capable of long-term self-renewal in culture, while maintaining multipotency in several species, such as human, mouse, canine and bovine ([@b33-ajas-26-4-588-19]; [@b31-ajas-26-4-588-19]; [@b13-ajas-26-4-588-19]; [@b30-ajas-26-4-588-19]). However, the presence of a multipotent stem cell population in canine tissues has not yet been fully investigated. Therefore, it is considered important to isolate and characterize canine derived MSCs. For this purpose, we isolated umbilical cord-MSCs (cUC-MSCs) from umbilical cord matrix and subjected to proliferative culture for 5 consecutive passages. The MSCs at each passage were characterized by monitoring the transcriptional patterns of MSC-specific pluripotent and surface markers. Finally, chondrogenic differentiation potentials of cUC-MSCs were also tested.

MATERIAL AND METHODS
====================

Isolation of canine umbilical cord matrix (cUCM) cell and cell culture
----------------------------------------------------------------------

For this study, whole cUCMs were obtained from three female dogs (n = 3) during parturition. The whole cUCMs were first separated from amnion and fetuses. The cUCMs were washed with phosphate buffered saline (PBS) to remove blood. Amniotic epithelium surrounding umbilical cord and blood vessel were dissociated by sterile scissors and forceps, and incubated in 20 ml PBS containing 1X Pen Strep (penicillin 100 unit/ml streptomycin 100 μg/ml, GIBCO, USA ) and 0.05% trypsin/EDTA at 37°C for 1 h to remove remnant amniotic epithelium. Trypsin was inactivated by adding Hank's buffered salt solution supplemented with 10% fetal bovine serum (FBS). The processed cUCMs were cut into pieces of 1 to 2 mm size with scissors, and incubated in PBS containing 0.1% collagenase type I (Sigma) at 37°C for 30 min. The digested tissues were passed through cell strainer (BD, USA) (100 μm) to remove undigested tissues and centrifuged at 1,500 rpm for 10 min. The cell pellet was resuspended in a growth media, Dulbecco's Modified Eagles Medium (Invitrogen, USA) containing 1X Pen Strep (penicillin 100 unit/ml streptomycin 100 μg/ml, GIBCO, USA ) and 10% FBS, and cultured in tissue culture flask at 37°C in 5% CO~2~ incubator. After 2 d incubation, cell culture medium was changed with the fresh medium, and cells were passaged every 5 d. Cells at each passage were trypsinized to the single cell and further seeded to contain 5×10^4^ per well on a 6-well tissue culture plate and maintained for 5 d until 80 to 90% confluence was reached.

Cumulative population doubling level (CPDL)
-------------------------------------------

During continuous passages, the number of cUC-MSCs at both seeding and harvesting time were counted to calculate CPDL based on the formula "x = {log10(N~H~)-log10(N~I~)} log10" where N~I~ is the initial cell number and N~H~ is the harvest cell number. The cumulative doubling level was obtained by adding doubling level of each passage to that of the previous passage ([@b5-ajas-26-4-588-19]).

Cell doubling time calculation
------------------------------

Cell doubling times (DT) and numbers (CD) were calculated from hemocytometer counts and cell culture time (CT) for each passage by the formula CD = ln(N~f~/N~i~)ln2 and DT = CT/CD where N~i~ is the initial cell number and N~f~ is the harvest cell number ([@b26-ajas-26-4-588-19]).

Reverse transcriptase-polymerase chain reaction (RT-PCR) gene expression analysis
---------------------------------------------------------------------------------

RT-PCR primers for pluripotency (Oct3/4, Nanog, Sox2), MSC surface markers (CD4, CD8A, CD25, CD33, CD34, CD44, CD54, CD61, CD80, CD105, CD117, Flk-1 and HMGA2) and GAPDH internal control were shown in [Table 1](#t1-ajas-26-4-588-19){ref-type="table"}. Total RNA was extracted from the cUCM-MSCs using TRIzol (Invitrogen, USA). RNA concentration was measured by absorbance at 260 nm with a spectrophotometer (Thermo, USA), and cDNA was generated using total RNA (2 μg), reverse primers (10 pmol per each) and Superscript II reverse transcriptase (Invitrogen, USA). For pluripotency marker analysis, target genes were amplified in 35 cycles of 94°C (30 s), 55°C to 60°C (30 s), 72°C (20 s), followed with 72°C for 10 min. For MSC CD marker analysis, the target genes were amplified in 35 cycles of 94°C (30 s), 57°C to 60°C (30 s), 72°C (30 s), followed with 72°C for 10 min. For differentiation marker analysis, target genes were amplified in 25 cycles of 94°C (30 s), 58°C to 64°C (30 s), 72°C (30 s), followed with 72°C for 10 min. Each sample was analyzed in triplicate. PCR products were separated on 2% agarose gel by electrophoresis, stained with Red Safe (iNtRon Biotechnology, Korea), and visualized under UV light. Images were digitally captured with a CCD camera (Gel Doc., USA).

Quantitative real-time PCR
--------------------------

Primers for differentiation markers (Sox9, Aggrecan precursor, Collagen type 2 alpha (COL2A)) and GAPDH internal control were shown in [Table 2](#t2-ajas-26-4-588-19){ref-type="table"}. Total RNA was extracted from the differentiated cells and cDNA (5 μl) of reverse polymerase transcription was used for PCR analysis. The qRT-PCR analysis was carried out in 96-well plates with using LightCycler 480 SYBR Green I Master kit (Roche Diagnostics, Germany). The following program was used for amplification: predenaturation for 10 min at 95°C, followed by 40 cycles of denaturation for 10 s at 95°C, annealing for 10 s at 61°C, and elongation for 10 s at 72°C. Melting curve analysis was performed from 65°C to 97°C to assess the specificity of the qRT-PCR products. Reference genes (GAPDH) that are stably expressed at 61°C were used for quantification. Based on the experiment analysis, we calculated qRT-PCR result by using Ct value.

*In vitro* differentiation
--------------------------

For chondrogenic differentiation, 1.6×10^7^ cells in 5 μl droplets were cultured to maintain hypoxia condition in the growth media at 37°C in 4-well tissue culture plate under the presence of 5% CO~2~ and then subjected to chondrogenic differentiation medium containing transforming growth factor beta 3 (TGF-β3; PT-3003, PT-4124 Lonza Walkersville, USA) for 21 d. All the differentiation media were changed every 2 to 3 d, and the differentiation was evaluated after 21 d.

Cytochemical staining
---------------------

The differentiated cells were washed twice with PBS, fixed with 4% formalin for 10 min and were subjected to cytochemical staining to confirm the lineage specific markers according to the manufacturer's protocols. Chondrogenic differentiation was confirmed with Alcian blue stain kit (NovaUltra^™^, IHC World, USA) by detecting glycosaminoglycan stained in blue color.

Statistical analysis
--------------------

Cell doubling time and relative expression of differentiation marker genes were analyzed by one-way analysis of variance test or Student's *t* test (JMP^®^ 6.0; SAS Institute Inc., Cary NC, USA). The graphs were prepared using SigmaPlot (ver. 8.0) (Systat Software, Inc., Point Richmond, CA, USA).

RESULTS AND DISCUSSION
======================

Cell growth and proliferation kinetics
--------------------------------------

cUC-MSCs were isolated from cUCM and grown in plastic tissue culture flasks. The cells were passaged every 5 d and counted for the number of cells grown after trypsinization. The cells were adherent to the plastic culture plates, and had fibroblast-like spindle shape, forming highly homogenous monolayer ([Figure 1A](#f1-ajas-26-4-588-19){ref-type="fig"}). During five consecutive passages, CPDL of the cells was linearly increased until fourth passage (P4), but decreased thereafter ([Figure 1B](#f1-ajas-26-4-588-19){ref-type="fig"}). In accordance with the CPDL, doubling time was not significantly increased in passage 2 or 3 (4.1/4.5 d) and P4 (5.8 d) vs P1 (3.6 d). However, the doubling time was significantly increased in P5 (16.7 d) versus P4 (5.8 d) (p\<0.05; [Figure 1C](#f1-ajas-26-4-588-19){ref-type="fig"}).

Expression of pluripotency markers
----------------------------------

Expression of pluripotency markers was tested using RT-PCR (Oct3/4, Nanog and Sox2; [Figure 2](#f2-ajas-26-4-588-19){ref-type="fig"}). Expression of Oct3/4 decreased with increasing the number of subpassage. However, expression of Nanog and Sox2 was negatively correlated with the number of subpassage.

Immunophenotyping of cUCM-MSCs
------------------------------

Expression of MSC surface markers such as CD4, CD8A, CD25, CD33, CD34, CD44, CD54, CD61, CD80, CD90, CD105, CD117, Flk-1and HMGA2 were conducted using RT-PCR. It was shown that cUC-MSCs were positive for CD44, CD54, CD61, CD80, CD90, CD105, Flk-1and HMGA2, but negative for CD4, CD8A, CD25, CD33, CD34 and CD117 ([Figure 3](#f3-ajas-26-4-588-19){ref-type="fig"}). In addition, the expression of CD44, CD54, CD61, CD80, CD90, Flk-1and HMGA2 were negatively correlated with the number of subpassage, but the expression of CD105 decreased with increasing the number of subpassage.

Chondrogenic differentiation
----------------------------

The cUC-MSCs were cultured for chondrogenic differentiation for 21 d in specific media. It was apparent that glycosaminoglycans formed in the differentiated cells were stained in blue color by alcian blue ([Figure 4A](#f4-ajas-26-4-588-19){ref-type="fig"}). It was confirmed by alcian blue staining that all cUCM-MSCs from passage 1 and 5 underwent chondrogenic differentiation, but those in early versus late passage displayed more intense glycosaminoglycan staining. Gene expression of markers associated with chondrogenic differentiation such as COL2A (late chondrogenic marker), Aggrecan precursor and Sox9 (early chondrogenic marker) was evident in differentiated cUC-MSCs compared with the undifferentiated cUC-MSCs ([Figure 4B](#f4-ajas-26-4-588-19){ref-type="fig"}). In real-time RT-PCR, the dramatic increases in Sox9 and Aggrecan precursor mRNA transcripts were observed in cells from passage 4 and 3 which cultured in chondrogenic medium. However, COL2A mRNA transcripts were significantly decreased with increasing the number of subpassage.

It is well known that MSCs have remarkable potential as a cell-mediate repair and regenerative medicine for fatal or incurable diseases, such as spinal cord injury, arthritis, cartilage regeneration and ischemic heart injury, as demonstrated in the field of stem cell therapy ([@b15-ajas-26-4-588-19]; [@b25-ajas-26-4-588-19]; [@b9-ajas-26-4-588-19]; [@b23-ajas-26-4-588-19]). In the present study, it was aimed to determine the effects of serial passaging (P1 to P5) on the growth, gene expression of MSC CD markers and chondrogenic differentiation potential of cUCM-MSCs.

There was no significant difference in the population doubling time from P1 to P4 (3.6 to 5.8 d), but P5 cells displayed a significantly longer doubling time (16.7 d). This result is consistent with the study by [@b28-ajas-26-4-588-19] who found that human ASC doubling times were significantly longer at passage 6 and later. In addition to the slower growth, changes in response to chemical stimuli were observed after passage 4 ([@b28-ajas-26-4-588-19]). Recent studies reported by [@b6-ajas-26-4-588-19] and [@b30-ajas-26-4-588-19] showed that increasing doubling times were found in human and bovine adipose stem cells (ASCs) at later passage.

It was found that the cUCM-MSCs expressed pluripotent markers (Oct3/4, Nanog and Sox2) and possessed several surface markers such as CD44, CD54, CD61, CD80, CD90, CD105, Flk-1and HMGA2. However, expression of Oct3/4 was decreased with increasing the number of subpassage. In addition, the expression of Nanog and Sox2 was negatively correlated with the number of subpassage. It was reported that transcription factors such as Nanog, Rex1, Fzd9, Oct4, Sox2 and Bst1 genes were essential in pluripotency maintenance as well as self-renewal ([@b19-ajas-26-4-588-19]). In study with ASCs, long-term cultures from passage 5 to 15 decreased stemness gene expression levels ([@b29-ajas-26-4-588-19]), indicating the negative correlation between the differentiation capability and serial passage of MSCs as seen in this study. Serial passaging has also been found to alter surface marker expression in human adipose-derived MSCs ([@b14-ajas-26-4-588-19]). [@b14-ajas-26-4-588-19] demonstrated that the percentage of cells expressing stroma cell markers, including CD105 and CD166 increased with subculture up to passage 4. However, we found that the expression of CD105 was decreased at passage 3 to 5.

The key role of CD105 in promoting MSC chondrogenesis may be related to its function as a member of TGF-β receptor superfamily. CD105 is a dimeric membrane glycoprotein expressed at high levels on human vascular endothelial cells. It shares regions of sequence identity with beta-glycan, a major binding protein for TGF-β, and thus plays an important role in modulating cellular responses to TGF-β ([@b4-ajas-26-4-588-19]; [@b2-ajas-26-4-588-19]). Since TGF-β is the most crucial factor that directs chondrogenesis and chondrogenic differentiation of MSCs ([@b12-ajas-26-4-588-19]; [@b10-ajas-26-4-588-19]), CD105 expression is probably linked to TGF-β mediated chondrogenesis in MSCs.

It is well known that alcian blue staining is a better indicator of the differentiation state of the MSC. In this study the intense of glycosaminoglycan was more pronounced in the early versus late passage MSCs, indicating an enhanced chondrogenesis in the early passage cells.

In addition, gene expression of markers associated with chondrogenic differentiation such as a COL2A, Aggrecan precursor and Sox9 were evident, but the pattern was different between MSCs passages. This observation supports that serial passage also influenced transcriptional levels of differentiation-associated markers in MSCs. Similarly, our gene expression results corroborate with the previous studies that lower expression of Sox9 ([@b8-ajas-26-4-588-19]), collagen II and aggrecan were found in the P5-induced pellets ([@b30-ajas-26-4-588-19]).

In conclusion, the present study demonstrated that sequential subpassages affect multipotent properties of cUC-MSCs, which should be considered in the trial of therapeutic application of cUC-MSCs.
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![Morphology (P1--P6) (40X) (A) and cumulative population doubling level (B) and doubling time (C) of cUC-MSC during continuous passages. Data are expressed as the mean±standard error of values obtained by two determinations. \* p\<0.05.](ajas-26-4-588-19f1){#f1-ajas-26-4-588-19}

![Expression of pluripotency markers (Oct3/4, Nanog and Sox-2) in cUC-MSC during continuous passages by RT-PCR. GAPDH was used as a control. The cells were positive for all markers.](ajas-26-4-588-19f2){#f2-ajas-26-4-588-19}

![Expression of MSC surface markers in cUC-MSC during continuous passages by RT- PCR. The results indicated that the cUC-MSCs were positive for CD44, CD54, CD61, CD80, CD90, CD105, Flk-1 and HMGA2, while negative for CD4, CD8A, CD25, CD33, CD34 and CD117.](ajas-26-4-588-19f3){#f3-ajas-26-4-588-19}

![Differentiation potential of cUC-MSC into mesodermal cell lineage, (A) chondrocyte (Alcian blue). The staining was conducted at 21 d after cells were grown in differentiation media. cUC-MSC showed induction of chondrogenic differentiation. Expression levels of chondrogenic (B) differentiation marker genes were compared between undifferentiated and differentiated cells by Real-time PCR. The expression levels were shown as the mean±standard error of the mean (n = 3). \*: p\<0.0001 vs undifferented cells.](ajas-26-4-588-19f4){#f4-ajas-26-4-588-19}

###### 

Primer sequences used for RT-PCR analyses in this study

  Markers/gene                       Primer sequence (5′-3′)            Amplification size (bp)   Reference
  ---------------------------------- ---------------------------------- ------------------------- ----------------
  Pluripotency                                                                                    
    OCT3/4                           Forward TGACGACAACAAAAATCT         128                       Vaags et al.
  Reverse CAGGCATGTGTTCTCCAG                                                                      
    NANOG                            Forward CCTGCATCCTTGCCAATGTC       98                        Vaags et al.
  Reverse TCCGGGCTGTCCTGAGTAAG                                                                    
    SOX2                             Forward AACCCCAAGATGCACAACTC       152                       Vaags et al.
  Reverse CGGGGCCGGTATTTATAATC                                                                    
  MSC makers                                                                                      
    CD4                              Forward TGCTCCCAGCGGTCACTCCT       381                       XM534906
  Reverse GCCCTTGCAGCAGGCGGATA                                                                    
    CD8A                             Forward GAGGAATGAGCCAGCCGCCC       303                       NM001002935.2
  Reverse GGAGACACCGGCTTGGACGC                                                                    
    CD25                             Forward GGCAGCTTATCCCACGTGCCAG     364                       AB501356.1
  Reverse ATGGGCGGCGTTTGGCTCTG                                                                    
    CD33                             Forward TTCGGCACGAGGCCAGGACC       364                       DR105786.1
  Reverse GCTGGCTCCACAACTGGGTGG                                                                   
    CD34                             Forward GCCTGCTCAGTCTGCTGCCC       255                       Filioli et al.
  Reverse TGGTCCCAGGCGTTAGGGTGA                                                                   
    CD44                             Forward GCCCTGAGCGTGGGCTTTGA       268                       Filioli et al.
  Reverse TCTGGCTGTAGCGGGTGCCA                                                                    
    CD54                             Forward TCCGTGGACCCAGCAGAAGC       468                       XM542075
  Reverse GCGGCACGAGAAGTTGGCGA                                                                    
    CD61                             Forward GAGGATTGCGCTGCGGCTCC       412                       NM001003162.1
  Reverse AAAGCCGCCCTCTGGGGCAT                                                                    
    CD80                             Forward GCCTCACCTCTCCTGGTGGGA      369                       AF257653.1
  Reverse TGGCCATACCTGTACAGTGACCTT                                                                
    CD105                            Forward GGTTCACTGCATCAACATGG       278                       XM546483.2
  Reverse AAGCTGAAGCGCACATCACC                                                                    
    CD117                            Forward CTCAGGGGGTGCGAGGGGAA       332                       AF099030.1
  Reverse TGTGTCTGTGCATTAGTCTGGCTG                                                                
    Flk-I                            Forward CTCCGCACCACATCCGCTGG       337                       XM539273
  Reverse TCCTGCTCGGTTGGCTGGGT                                                                    
    HMGA2                            Forward AGTCCCTCCAAAGCAGCTCAAAAG   75                        NM003484.1
  Reverse GCCATTTCCTAGGTCTGCCTC                                                                   
  Housekeeping                                                                                    
    GAPDH                            Forward AGTCAAGGCTGAGAACGGGAAACT   114                       Vieira et al.
  Reverse TCCACAACATACTCAGCACCAGCA                                                                

###### 

Primer sequences used for quantitative PCR analyses in this study

  Markers/Gene                         Primer sequence (5′-3′)            Amplification size (bp)   Reference
  ------------------------------------ ---------------------------------- ------------------------- ---------------
  Chondrocytes                                                                                      
    COL2A                              Forward ATCGGGCCTGTCTGCTTCTTGTAA   134                       Vieira et al.
  Reverse ACATCAGGTCAGGTCAGCCATTCA                                                                  
    SOX9                               Forward ACGACTACACTGACCACCAGAACT   88                        Vieira et al.
  Reverse ATGTAGGTGAAGGTGGAGTAGAGGCT                                                                
    Aggrecan                           Forward ACAATGCCCAAGACTACCAGTGGA   166                       Vieira et al.
  Reverse TTCTCGTGCCAGATCATCACCACA                                                                  
  Housekeeping                                                                                      
    GAPDH                              Forward AGTCAAGGCTGAGAACGGGAAACT   114                       Vieira et al.
  Reverse TCCACAACATACTCAGCACCAGCA                                                                  

[^1]: Department of Animal Biotechnology, Konkuk University, Seoul, Korea, 120 Neungdong-ro, Gwangjin-gu 143-701, Korea.

[^2]: Research Planning Division, Animal, Plant and Fisheries Quarantine and Inspection Agency, Anyang 6-dong, Anyang-si, Gyeonggi-do 430-757, Korea.

[^3]: These authors **c**ontributed equally to this work.
